drugset
drugset / Trial / NCT05279677

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

NCT05279677 ↗

Phase 2 Unknown 30 enrolled Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

A single-arm, phase II study was designed to evaluate the efficacy and safety of fecal microbiota transplantation plus Sintilimab and Fruquintinib as the later line treatment in colorectal patients with advanced stages.

Timeline

Start
2022-08-12
Primary completion
2023-10
Completion
2024-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule 5 mg Oral
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

colorectal cancer